182 related articles for article (PubMed ID: 30167089)
1. A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.
Rodon J; Curigliano G; Delord JP; Harb W; Azaro A; Han Y; Wilke C; Donnet V; Sellami D; Beck T
Oncotarget; 2018 Aug; 9(60):31709-31718. PubMed ID: 30167089
[TBL] [Abstract][Full Text] [Related]
2. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
4. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer.
Sharma P; Abramson VG; O'Dea A; Nye L; Mayer I; Pathak HB; Hoffmann M; Stecklein SR; Elia M; Lewis S; Scott J; De Jong JA; Wang YY; Yoder R; Schwensen K; Finke K; Heldstab J; LaFaver S; Williamson SK; Phadnis MA; Reed GA; Kimler BF; Khan QJ; Godwin AK
Clin Cancer Res; 2021 Jul; 27(14):3896-3904. PubMed ID: 33602685
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor.
Pantaleo MA; Heinrich MC; Italiano A; Valverde C; Schöffski P; Grignani G; Reyners AKL; Bauer S; Reichardt P; Stark D; Berhanu G; Brandt U; Stefanelli T; Gelderblom H
BMC Cancer; 2022 May; 22(1):511. PubMed ID: 35524239
[TBL] [Abstract][Full Text] [Related]
7. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
Tsang ES; Aggarwal RR; Dhawan MS; Bergsland EK; Alvarez EA; Calabrese S; Pacaud R; Garcia J; Fattah D; Thomas S; Grabowsky J; Moasser MM; Munster PN
Cancer Res Commun; 2022 Jul; 2(7):570-576. PubMed ID: 36923283
[TBL] [Abstract][Full Text] [Related]
8. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Rugo HS; André F; Yamashita T; Cerda H; Toledano I; Stemmer SM; Jurado JC; Juric D; Mayer I; Ciruelos EM; Iwata H; Conte P; Campone M; Wilke C; Mills D; Lteif A; Miller M; Gaudenzi F; Loibl S
Ann Oncol; 2020 Aug; 31(8):1001-1010. PubMed ID: 32416251
[TBL] [Abstract][Full Text] [Related]
9. Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Wheler J; Mutch D; Lager J; Castell C; Liu L; Jiang J; Traynor AM
Oncologist; 2017 Apr; 22(4):377-e37. PubMed ID: 28275119
[TBL] [Abstract][Full Text] [Related]
10. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
Curigliano G; Martin M; Jhaveri K; Beck JT; Tortora G; Fazio N; Maur M; Hubner RA; Lahner H; Donnet V; Ajipa O; Li Z; Blumenstein L; Andre F
Eur J Cancer; 2021 Jul; 151():49-62. PubMed ID: 33964572
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors.
Ando Y; Iwasa S; Takahashi S; Saka H; Kakizume T; Natsume K; Suenaga N; Quadt C; Yamada Y
Cancer Sci; 2019 Mar; 110(3):1021-1031. PubMed ID: 30588709
[TBL] [Abstract][Full Text] [Related]
12. Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
Williams NO; Quiroga D; Johnson C; Brufsky A; Chambers M; Bhattacharya S; Patterson M; Sardesai SD; Stover D; Lustberg M; Noonan AM; Cherian M; Bystry DM; Hill KL; Chen M; Phelps MA; Grever M; Stephens JA; Ramaswamy B; Carson WE; Wesolowski R
Ther Adv Med Oncol; 2023; 15():17588359231217976. PubMed ID: 38152697
[TBL] [Abstract][Full Text] [Related]
13. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
15. A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
Rodón J; Demanse D; Rugo HS; Burris HA; Simó R; Farooki A; Wellons MF; André F; Hu H; Vuina D; Quadt C; Juric D
Breast Cancer Res; 2024 Mar; 26(1):36. PubMed ID: 38439079
[TBL] [Abstract][Full Text] [Related]
16. Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.
Pant S; Hamilton E; Ulahannan SV; Strauss JF; Braiteh FS; Huang M; Liaw DCH
Cancer; 2023 Jun; 129(12):1919-1929. PubMed ID: 36970876
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
Spicer J; Irshad S; Ang JE; Enting D; Kristeleit R; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J
Cancer Chemother Pharmacol; 2017 Jan; 79(1):17-27. PubMed ID: 27872953
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
19. Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors.
Gordon MS; Shapiro GI; Sarantopoulos J; Juric D; Lu B; Zarotiadou A; Connarn JN; Le Bruchec Y; Dumitru CD; Harvey RD
Front Oncol; 2021; 11():786120. PubMed ID: 35070991
[TBL] [Abstract][Full Text] [Related]
20. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
